MA-2029

an orally-active motilin receptor antagonist with a modified tripeptide backbone; inhibits motilin-induced intestinal contractions and visceral pain in rabbits; structure in first source

Also Known As:

(S)-N-(S)-((2-(3-tert-butyl-4-hydroxy-phenyl)-1-ethylcarbamoyl-ethyl)-3-methyl-2-methyl-((S)-2-methylamino-3-phenyl-propionyl)amino)butyramide hydrochloride

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - MA-2029: 3

Experts

1.	Cynshi, Osamu: 2 articles (08/2009 - 03/2008)
2.	Kamei, Kenshi: 2 articles (08/2009 - 03/2008)
3.	Kuromaru, Osamu: 2 articles (08/2009 - 03/2008)
4.	Muramatsu, Hiroyasu: 2 articles (08/2009 - 03/2008)
5.	Onoma, Mitsu: 2 articles (08/2009 - 03/2008)
6.	Ozaki, Ken-ichi: 2 articles (08/2009 - 03/2008)
7.	Peeters, Theo L: 2 articles (08/2009 - 03/2008)
8.	Sudo, Hirokazu: 2 articles (08/2009 - 03/2008)
9.	Takanashi, Hisanori: 2 articles (08/2009 - 03/2008)
10.	Yogo, Kenji: 2 articles (08/2009 - 03/2008)

Related Diseases

1.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/01/2008 - "The aim of this study was to assess the cardiovascular effect of MA-2029, a selective motilin receptor antagonist highly expected for the treatment of irritable bowel syndrome (IBS). "
2.	Hypotension (Low Blood Pressure) 12/01/2008 - "In the cardiovascular study, MA-2029 at 30 mg/kg induced slight cardiovascular changes such as hypotension, QTc shortening, and PR prolongation possibly caused by Ca(2+) channel blockade. "
3.	Visceral Pain 03/10/2008 - "Furthermore, the oral administration of MA-2029 (0.3 to 3 mg/kg) also inhibited abdominal muscle contractions (an index of the visceral pain) induced by intravenous infusion of motilin (3 microg/kg/h) during colorectal distension in conscious rabbits. " 03/10/2008 - "Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits."
4.	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 08/01/2009 - "MA-2029 may be useful in treating gastrointestinal disorders in which the pathogenesis involves the elevation of circulating motilin."
5.	Diarrhea 08/01/2009 - "MA-2029 (1-30 mg/kg, p.o.) reduced the incidence of diarrhea induced by motilin in a dose-dependent manner. " 08/01/2009 - "An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying."

Related Drugs and Biologics

1.	motilin receptor
2.	Motilin

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Oral Administration